MedAware names new scientific advisory board member.
M2 PHARMA-July 9, 2019-MedAware names new scientific advisory board member
(C)2019 M2 COMMUNICATIONS
MedAware, a developer of AI-based patient safety solutions, announced yesterday that it has named Dr John Halamka, MD, MS as its new member of the scientific advisory board.
Presently, Dr Halamka serves as executive director of Beth Israel Lahey Health Technology Exploration Center. He also leads innovation for Beth Israel Lahey Health, serves as chairman of the New England Healthcare Exchange Network (NEHEN), is the International Healthcare Innovation professor at Harvard Medical School, and is a practicing emergency physician. Previously, Dr Halamka served as chief information officer at the Beth Israel Deaconess Healthcare System. Over the past decade, Dr Halamka has written and co-authored several papers on the need for Electronic Health Records and how prescription errors can be mitigated, having personally been affected by such an error.
Dr Halamka said, 'Quality and safety depend on a level of decision support not found inside the EHR itself, hence the need for novel services and apps like MedAware. We will begin to see the next generation of innovation and safety belongs to cloud hosted services companies and apps that layer on top of existing EHRs. MedAware is well poised to be a leader in this app economy.'
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 9, 2019|
|Previous Article:||StemoniX to open new California research & development facility.|
|Next Article:||icotec AG awarded US FDA clearance to market VADER one pedicle screw system for spinal surgeries.|